, K 2P 2.1 cryst responds to both ML335 and ML402 (Extended Data Fig. 2f-i) . The ML335/ML402 binding pocket differs from the TREK antagonist norfluoxetine 6 binding site ( Fig. 1e ) and is dissimilar to other VGIC superfamily pore domain antagonist sites 18, 19 (Extended Data Fig. 3) . Thus, the ML335/ML402 site, dubbed the 'K 2P modulator pocket' , establishes a novel point for VGIC superfamily small molecule modulation.
The K 2P modulator pocket comprises a 'P1 face' and an 'M4 face' that form a common set of hydrogen bonds, π -π , and cation-π 20 interactions with ML335 and ML402 (Fig. 2a, b and Extended Data Fig. 4a, b) . Both compounds adopt an L-shaped conformation enabling their 'upper ring' (ML335 N-aryl sulfonamide and ML402 thiophene) and 'lower ring' (ML335 dicholoro-benzyl and ML402 aryl ether) to engage the P1 helix residue Phe134 through face-face and edge-face interactions, respectively (Fig. 2a, b) . On the M4 face, the upper and lower rings make a cation-π interaction with Lys271 and edge-face interaction with Trp275, respectively ( The amide groups of both compounds also make hydrogen bonds with the Ala259 carbonyl on the loop connecting the second selectivity filter. The ML335 sulfonamide forms additional interactions with the Gly260 carbonyl on the same loop, the P1 face Ser131 hydroxyl, the 111-128 loop His126 imidazole nitrogen, and Asn147 on the first selectivity filter (Fig. 2a, Extended Data Fig. 4a ).
The K 2P modulator pocket constitutes a cryptic binding site requiring conformational changes centred around Phe134, Lys271 and Trp275 (Fig. 2c, d , Supplementary Video 1). Without activators, Phe134 and the M4 helix N-terminal end occlude the pocket. These elements move towards the selectivity filter and away from the P1 helix, respectively, to allow access. Lys271 and Trp275 are mobile in the unliganded structure (Extended Data Figs 5a and 6b), change conformation to form modulator interactions, and together with Phe134 have reduced bound state mobility (Extended Data Fig. 5a -c, and Extended Data Table 2a ). Hence, both compounds act as wedges driven into the selectivity filter supporting structure, a mode reminiscent of other channel modulators 21, 22 . Notably, the K 2P modulator pocket includes gainof-function mutation sites, Gly137 and Trp275, affecting all TREK subfamily members 7, 8, 15, 23 (Extended Data Fig. 6b ). Together, these observations indicate that the P1-M4 interface is a hub for conformational changes causing TREK subfamily activation and that P1-M4 interface stabilization is central to ML335 and ML402 action.
K 2P activator pocket residues that contact the compounds are identical among TREK subfamily members, except for the Lys271 cation-π interaction, and diverge in other K 2P subtypes (Extended Data Fig. 4c, d ).
Comparison with K 2P 10.1 6 and K 2P 4.1 (TRAAK) 4,13-15 (Extended Data Fig. 6a , Extended Data Table 2b ) reveals no selectivity filter conformation differences. This structural similarity supports the idea that ML335 and ML402 influence selectivity filter dynamics, similar to inferences from structural studies of P1-M4 interface gain-of-function mutants 15 . There are notable differences in the first two M4 helical turns of the K 2P modulator pocket and the conformations of the Phe134 and Trp275 equivalent positions among TREK subfamily structures (Extended Data Fig. 6b-f ).
Given the varied conformations of these residues in the absence of activators and mobility changes between the unliganded and liganded structures (Extended Data Fig. 5 ), the main action of the activators appears to be to limit the conformations sampled by P1-M4 interface elements.
The K 2P 2.1 C-tail senses phospholipid 24,25 , phosphorylation 26,27 , temperature 7, 28 , and pressure 27 gating commands and forms a continuous helix with M4 (Fig. 3a) . Prior TREK subfamily structures uncovered varied M4 conformations spanning extremes termed 'up' and 'down' 4, 6, [13] [14] [15] . Proposals that the up 14 , down 15 , or both conformations are active 6, 23 , have been advanced. In all K 2P 2.1structures, M4 is up (Fig. 1a) and the selectivity filter sites S1-S4 are occupied by potassium ions (Extended Data Fig. 6a ). Because both C-tails make lattice contacts (Extended Data Fig. 1g ) that can influence M4 13, 15 , the K 2P 2.1 structures presented here cannot directly address the controversy regarding M4 status. Nevertheless, the activator-bound selectivity filter is compatible with the up M4 conformation.
The C-tail has two faces, an electropositive patch comprising four residues implicated in PIP 2 modulation (Arg297, Lys301, Lys302 and Lys304) 24, 25 , and a face housing the intracellular proton sensor site, Glu306
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, and inhibitory phosphorylation site, Ser300 26 ( Fig. 3a, b) . The channel electrostatic profile shows a second positively charged region at the M1-M2-M4 junction (Fig. 3b) suggesting that the resultant interhelical groove may be a phospholipid binding site.
All three K 2P 2.1 structures revealed tubular densities at locations different from previous K 2P lipid binding sites 4, 6, 14, 15 , denoted as lipids L1, L2, and L3 (Fig. 3c, Extended Data Fig. 1e, f) . L1 resides at the M2-P2 inter-subunit junction (Fig. 3c ). L2 and L3 are part of a single phospholipid (Extended Data Fig. 1e, f) and sit in the groove formed by the positively charged M1-M2-M4 inter-subunit junction (Fig. 3b, c and Extended Data Fig. 1e, f) . The L2-L3 site seems to be a prime point for modulatory lipids, as the positively charged residues that affect PIP 2 responses 24,25 are on the helical face opposite to L2-L3, and M4 conformational changes could affect how these residues interact with regulatory lipid head-groups.
Xenopus oocyte two-electrode voltage-clamp measurements show that ML335 and ML402 activate K 2P 2.1and K 2P 10.1 but not K 2P 4.1 (14.3 ± 2.7 μ M, K 2P 2.1-ML335; 13.7 ± 7.0 μ M, K 2P 2.1-ML402; 5.2 ± 0.5 μ M, K 2P 10.1-ML335; and 5.9 ± 1.6 μ M, K 2P 10.1-ML402) (Fig. 4a-f and Extended Data Fig. 7a-c) . The K 2P modulator pocket has a single difference among TREK subfamily members at the cation-π interaction position, K 2P 2.1 Lys271 (Extended Data Fig. 4c) , which is also a lysine in K 2P 10.1 but a glutamine in K 2P 4.1. Hence, we Fig. 7d-g ). K 2P 2.1(K271Q) was insensitive to ML335 and ML402, whereas K 2P 4.1(Q258K) responded to both with a similar EC 50 to K 2P 2.1(14.3 ± 2.7 μ M, K 2P 2.1-ML335; 16.2 ± 3.0 μ M, K 2P 4.1(Q258K)-ML335; 13.7 ± 7.0 μ M, K 2P 2.1-ML402; 13.6 ± 1.5 μ M, K 2P 4.1(Q258K)-ML402) but with a lower magnitude response than K 2P 2.1. Notably, the effects of TREK subfamily activators arachidonic acid 27, 30 , BL-1249 31, 32 , and ML67-33 11 were unchanged (Extended Data Fig. 7h-k) . To probe the cation-π interaction further, we synthesized a ML335 congener, ML335a, in which the aromatic upper ring was replaced with an aliphatic ring (Fig. 4c) . ML335a had no effect on K 2P 2.1 (Fig. 4c) , supporting the importance of the cation-π interaction. Together, these data identify the Lys271 cation-π interaction as the origin of ML335/ML402 subtype selectivity and establish that this interaction is essential for activation.
The principal K 2P channel gating site is the selectivity filter C-type gate 7-10 . This gate is highly sensitive to permeant ions 8,16,17 and is thought to function via 'flux gating' whereby outward, but not inward, ion flow stabilizes the active conformation 9 . Physiological K 2P 2.1 activators, such as arachidonic acid, PIP 2 , and intracellular acidification, shift the channel from outward rectifier mode to an ohmic 'leak mode' 9 . Because the K 2P modulator pocket contains architectural elements that support the activator selectivity and gain-of-function mutants that activate the C-type gate 7, 8, 15 , we asked whether structural changes to the P1-M4 interface caused by ML335, ML402, or gain-offunction mutations affect C-type gate function.
Measurement of K 2P 2.1 in inside-out patches under conditions that potentiate flux-dependent C-type gate activation (150 mM
9 showed the expected outward rectification (Fig. 4g, k) . . c, ML335 dose-response curves for K 2P 2.1 (black), EC 50 = 14.3 ± 2.7 μ M (n ≥ 5); K 2P 2.1(K271Q) (blue filled circles); K 2P 4.1 (orange); and K 2P 4.1(Q258K) (green), EC 50 = 16.2 ± 3.0 μ M (n ≥ 4); and K 2P 2.1-ML335a (black open triangles). d, e, Exemplar current traces for K 2P 2.1 (black) with 20 μ M ML402 (purple) (d) and K 2P 4.1 (black) with 50 μ M ML335 (orange) (e). f, ML402 dose-response curves for K 2P 2.1 (black), EC 50 = 13.7 ± 7.0 μ M (n ≥ 3); K 2P 2.1(K271Q) (blue); K 2P 2.1 (blue); K 2P 4.1 (orange); and K 2P 4.1(Q258K) (green), EC 50 = 13.6 ± 1.5 μ M (n ≥ 3). g-j, Exemplar current traces and voltage-current relationships for indicated K 2P channels in HEK293 inside-out patches in 150 mM
for K 2P 2.1 (g), K 2P 2.1 with 5 μ M ML335 (h), K 2P 2.1 with 5 μ M ML402 (i), and K 2P 2.1(G137I) (j). k, Rectification coefficients (I +100 mV /I −100 mV ) from recordings (n ≥ 3) made in g-j. l, TREK activation model. Grey lines indicate mobile P1 (tan) and M4 (blue). C-type activators (orange) stabilize the selectivity filter and channel 'leak mode' . Potassium ions are purple. Gap in arrows indicates current flow intensity. Membrane is grey. ML335 and ML402 activate K 2P 2.1 in HEK293 cells similar to their effects in Xenopus oocytes (5.2 ± 0.8 μ M and 5.9 ± 1.6 μ M for ML335 and ML402, respectively (n ≥ 3)) ( Fig. 4g-i and Extended Data Fig. 8a ). Compound application essentially eliminated flux-dependent outward rectification (Fig. 4h, i , k) yielding a rectification coefficient (I +100 mV /I −100 mV ) of approximately 1. This outcome matches physiological activator effects 9 and establishes that ML335 and ML402 activate the C-type gate. The K 2P 4.1 gain-of-function mutation G124I reshapes the K 2P modulator pocket through structural consequences similar to ML335/ML402, namely an outward M4 movement and repositioning of the K 2P 2.1 Phe134 equivalent residue 15 (Extended Data Fig. 6f ). K 2P 2.1(G137I) and K 2P 4.1(G124I) 7,15 caused a similar mode shift and rectification coefficient change to ML335 and ML402 (Fig. 4j, k and Extended Data Fig. 8b-d) establishing that K 2P modulator pocket manipulation by ML335/ML402 binding or mutation directly activates the selectivity filter C-type gate. Together with the compound-bindinginduced mobility reduction of the P1-M4 interface (Extended Data Fig. 5 ) and lack of K 2P selectivity filter structural differences (Extended Data Fig. 6a ), our findings strongly support the idea that direct C-type gate activators stimulate function by reducing the dynamics of the selectivity filter and surrounding structure.
The roles of TREK channels in ischaemia, pain, analgesia and anaesthetic responses 1 suggest that TREK activators could provide new avenues for neuroprotection and pain control. Many natural TREK regulators are thought to act on the C-tail 7,24-29 and influence the C-type gate through M4 6-8,15,23 , the movement of which is targeted by the antagonist norfluoextine 6, 23 . In this regard, ML335 and ML402 represent a new K 2P modulator class, as they function by binding directly to a pocket at the heart of the channel active site, the C-type gate, rather than influencing the C-tail or M4.
The K 2P modulator pocket defines the first VGIC superfamily pore domain small-molecule activator site and differs from antagonist sites occupying lateral fenestrations below the selectivity filter 6,18 ( Fig. 1e  and Extended Data Fig. 3a) . Voltage-gated calcium channel antagonists, amlodipine and nifedipine 19 , act at an interface similar to the K 2P modulator pocket, but at a pore domain outer rim site normally occupied by lipids 19 (Extended Data Fig. 3b) . Notably, all of these small-molecule sites are found at interfaces that are thought to move during gating 6, 18, 19 , highlighting the potential of channel inter-subunit interfaces as small-molecule control sites.
Our findings provide a structural basis for understanding K 2P C-type gate activation. The K 2P modulator pocket in unliganded K 2P 2.1 displays mobility in key elements that is reduced upon activator engagement (Fig. 4l, Extended Data Figs 5, 6b-d and Supplementary Video 1) . Notably, the K 2P modulator pocket M4 helix N-terminal end, an important site for channel activation 8 and conduit for transmitting C-tail sensor domain cues to the C-type gate 7, 8 , adopts a similar position in the ML335 and ML402 K 2P 2.1 complexes and in K 2P 4.1(G124I) (Extended Data Fig. 6f ). As the remainder of M4 is 'up' for the K 2P 2.1 activator complexes, but 'down' for K 2P 4.1(G124I), the data support the idea that M4 position is not the sole determinant of channel state 23 . The importance of changes in P1-M4 interface dynamics explain how M4 can affect channel function and allow the up or down conformations to activate the channel 23 , as both states could limit the mobility of the P1/M4 interface. Such plasticity may be important for enabling TREK subfamily polymodal modulation. Our findings indicate that under basal conditions, K 2P 2.1 equilibrates between a resting state having a mobile P1-M4 interface and an activated state in which the mobility of this site is limited. ML335 and ML402 directly stabilize the C-type gate by acting like molecular wedges that reduce P1-M4 interface dynamics (Fig. 4l, Extended Data Fig. 5 and Extended Data Table 2a ) and cause the filter to enter the leak mode (Fig. 4h, i) , bypassing modulation mechanisms that may involve other channel regions. The K 2P modulator pocket properties revealed by our studies raise the possibility that natural processes or native signalling molecules may also target this site.
Opening the cryptic K 2P modulator pocket requires small movements of few residues, similar to soluble protein cryptic modulator sites 33 . K 2P modulator pocket diversity (Extended Data Fig. 4c, d) , the P1-M4 interface susceptibility to gain-of-function mutations 7, 8 , and demonstration that a single residue therein can define modulator selectivity suggests that this site may be amenable for K 2P subtype-selective pharmacology development. As the fundamental pocket architecture is conserved in the VGIC superfamily, similar modulatory mechanisms may exist in other superfamily members where selectivity-filter-based gating is central. Thus, this site should provide a fertile target for channel modulator discovery.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.
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No statistical methods were used to predetermine sample size. No randomization or blinding was used. Construct screening. A set of mutants and deletion constructs of mouse K 2P 2.1 1 bearing a C-terminal TEV protease cleavage site and GFP were expressed from a pcDNA3.1 in HEK293 cells and screened for expression level and peak quality using fluorescence-detection size-exclusion chromatography (FSEC) [34] [35] [36] . These efforts identified a construct, hereafter called K 2P 2.1 cryst , encompassing residues 21-322 and bearing the following mutations: K84R, Q85E, T86K, I88L, A89R, Q90A, A92P, N95S, S96D, T97Q, N119A, S300A, E306A. The first nine mutations are located on the surface of the cap domain and greatly increased expression. N119A targets a putative glycosylation site. S300A and E306A are previously studied mutants 7 that improved the biochemical properties of the purified protein. The reduced response of K 2P 2.1 cryst to ML335 and ML402 probably results from partial activation of the channel in a cellular context owing to the incorporation of the E306A mutation 7, 29 and is compatible with the model proposed in Fig. 4l in which basal activity is increased by E306A but can nevertheless be shifted to the C-type gate activated state by activator binding and C-type gate stabilization. Protein expression. K 2P 2.1 cryst bearing a C-terminal green fluorescent protein (GFP) and His 10 tag was expressed from a previously described Pichia pastoris pPICZ vector 4 . Plasmids were linearized with PmeI and transformed into P. pastoris SMD1163H by electroporation. Multi-integration recombinants were selected by plating transformants onto yeast extract peptone dextrose sorbitol (YPDS) plates having increasing concentrations of zeocin (1-4 mg ml
). Expression levels of individual transformants were evaluated by FSEC as previously described 15 . Large-scale expression was carried out in a 7L Bioreactor (Labfors5, Infors HT). First, a 250 ml starting culture was grown in buffered minimal medium (2× YNB, 1% glycerol, 0.4 mg l −1 biotin, 100 mM potassium phosphate, pH 6.0) in shaker flasks for two days at 29 °C. Cells were pelleted by centrifugation (3,000g, 10 minutes, 20 °C) and used to inoculate the bioreactor. Cells were grown in minimal medium (4% glycerol, 0.93 g l −1 CaSO 4 ·2H 2 O, 18.2 g l −1 K 2 SO 4 , 14.9 g l −1
MgSO 4 .7H 2 O, 9 g l −1 (NH 4 ) 2 SO 4 , 25 g l −1 Na + hexametaphosphate, 4.25 ml l −1 PTM 1 trace metals stock solution prepared accordingly to standard Invitrogen protocol) until the glycerol in the fermenter was completely metabolized marked by a spike in pO 2 (around 24 h). Fed-batch phase was then initiated by adding a solution of 50% glycerol and 12 ml l −1 of trace metals at 15-30% of full pump speed until the wet cell mass reached approximately 250 g l −1 (around 24 h). pO 2 was measured continuously and kept at a minimum of 30%. Feed rate was automatically regulated accordingly. pH was maintained at 5.0 by the addition of a 30% ammonium hydroxide solution.
After the fed-batch phase was completed, cells were then starved to deplete glycerol by stopping the feeder pump until a pO 2 spike appeared. After starvation, the temperature was set to 27 °C, and the induction was initiated with addition of methanol in three steps: (1) initially, the methanol concentration was kept at 0.1% for 2 h in order to adapt the cells; (2) methanol concentration was then increased to 0.3% for 3 h; and (3) methanol was then increased to 0.5% and expression continued for 48-60 h. Cells were then pelleted by centrifugation (6,000g,1 h, 4 °C), snap frozen in liquid nitrogen, and stored at − 80 °C. Protein purification. In a typical preparation, 50 g of cells were broken by cryo-milling (Retsch model MM400) in liquid nitrogen (5 × 3 min, 25 Hz). All subsequent purification was carried out at 4 °C. Cell powder was added at a ratio of 1 g cell powder to 3 ml lysis buffer (200 mM KCl, 21 mM OGNG (octyl glucose neopentyl glycol, Anatrace), 30 mM HTG (n-heptyl-β -d-thioglucopyranoside, Anatrace), 0.1% CHS, 0.1 mg ml −1 DNase 1 mM PMSF, 100 mM Tris-Cl, pH 8.2). Membranes were extracted for 3 h with gentle stirring followed by centrifugation (100,000g, 45 minutes at 4 °C).
Solubilized proteins were purified by affinity chromatography using batch purification. Anti-GFP nanobodies were conjugated with CNBr Sepharose beads (GE Healthcare, #17-0430-02) according to ref. 37 . The resin was added to the cleared supernatant at a ratio of 1 ml of resin per 10 g of cell powder and incubated at 4 °C for 3 h with gentle shaking. Resin was collected into a column and washed with ten column volumes (CV) of buffer A (200 mM KCl, 10 mM OGNG, 15 mM HTG, 0.018% CHS, 50 mM Tris-Cl, pH 8.0) followed by a second wash step using 10 CV of buffer B containing (200 mM KCl, 5 mM OGNG, 15 mM HTG, 0.018% CHS, 50 mM Tris-Cl, pH 8.0). The resin was then washed with additional ten CV of buffer C (200 mM KCl, 3.85 mM OGNG, 15 mM HTG, 0.0156% CHS, 50 mM Tris-Cl, pH 8.0). On column cleavage of the affinity tag was achieved by incubating the resin with buffer C supplemented to contain 350 mM KCl, 1 mM EDTA, and 3C protease 38 at ratio of 50:1 resin volume:protease volume. The resin was incubated overnight at 4 °C. Cleaved sample was collected and the resin washed with two CV of SEC buffer (200 mM KCl, 2.1 mM OGNG, 15 mM HTG, 0.012% CHS, 20 mM Tris-Cl, pH 8.0). Purified sample was concentrated and applied to a Superdex 200 column equilibrated in SEC buffer.
Crystallization and refinement. Purified K 2P 2.1 cryst was concentrated to 6 mg ml −1 by centrifugation (Amicon Ultra-15, 50 kDa molecular mass cut-off; Millipore) and crystallized by hanging-drop vapour diffusion at 4 °C using a mixture of 0.2 μ l of protein and 0.1 μ l of precipitant over 100 μ l of reservoir containing 20-25% PEG400, 200 mM KCl, 100 mM HEPES pH 8.0, 1 mM CdCl 2 . Crystals appeared in 12 h and grew to full size (200-300 μ M) in about a week. Crystals were cryoprotected with buffer D (200 mM KCl, 0.2% OGNG, 15 mM HTG, 0.02% CHS, 100 mM HEPES pH 8.0,1 mM CdCl 2 ) with 5% step increase of PEG400 up to a final concentration of 38% and flash-frozen in liquid nitrogen. K 2P 2.1 cryst ML335 and ML402 complex crystals grew in the same conditions as K 2P 2.1 cryst , but the protein was incubated for at least 1 h with 2.5 mM of activator before setting the crystal plates. ML335 and ML402 are insoluble in aqueous solutions, so they were dissolved in 100% DMSO at a concentration of 500 mM. Then each compound was diluted 1:100 in SEC buffer to 5 mM concentration, giving a milky solution. This solution was mixed 1:1 to K 2P 2.1 cryst previously concentrated to 12 mg ml −1
. The K 2P 2.1 crys /ML402 mixture resulted in a clear solution, while the mixture with ML335 was slightly milky. The samples were briefly centrifuged in a table-top centrifuge (10,000 g) to remove any insoluble material before setting the crystal plates.
Datasets for K 2P 2.1, K 2P 2.1-ML335, and K 2P 2.1-ML402 were collected at 100 K using synchrotron radiation at ALS Beamline 8. Final resolution cut-off was 3.1 Å, 3.0 Å and 2.8 Å for K 2P 2.1 cryst , K 2P 2.1 cryst -ML335 and K 2P 2.1 cryst -ML402, respectively, using the CC 1/2 criterion 41, 42 . Structures were solved by molecular replacement using the K 2P 4.1(G124I) structure (PDB: 4RUE) 15 as search model. Several cycles of manual rebuilding, using COOT 43 , and refinement using REFMAC5 44 and PHENIX 45 were carried out to improve the electron density map. Twofold local medium NCS restraints were employed during refinement for residues 28-103, 110-158 and 194-260. K 2P 2.1, K 2P 2.1-ML335 and K 2P 2.1-ML402 structures have, respectively, 95.2%/0.4%, 92.0%/0.5% and 95.7%/0.4% residues in favoured regions/outliers of the Ramachandran plot as assessed by Molprobity 46 . Patch-clamp electrophysiology. Mouse K 2P 2.1, human K 2P 4.1, and mutants were expressed from a previously described pIRES2-EGFP vector 8, 11 in HEK293T cells (ATTC). 70% confluent cells were transfected (in 35-mm diameter wells) with LipofectAMINE 2000 (Invitrogen) for 6 h, and plated onto coverslips coated with Matrigel (BD Biosciences).
Effects of ML335, ML402 and arachidonic acid on K 2P 2.1 current at 0 mV were measured by whole-cell patch-clamp experiments 24 h after transfection. Acquisition and analysis were performed using pCLAMP9 and an Axopatch 200B amplifier (Molecular Devices). Pipette resistance ranged from 1 to 1.5 MΩ . Pipette solution contained the following: 145 mM KCl, 3 mM MgCl 2 , 5 mM EGTA and 20 mM HEPES (pH 7.2 with KOH). Bath solution contained the following: 145 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 3 mM MgCl 2 and 20 mM HEPES (pH 7.4 with NaOH). K 2P 2.1 currents were elicited by a 1 s ramp from -100 to + 50 mV from a -80 mV holding potential. After stabilization of the basal current, ML335 and ML402 were perfused at 200 ml per hour until potentiation was stably reached.
Voltage-dependent activation of K 2P 2.1 was recorded on excised patches in inside-out configuration (50 kHz sampling) in the absence and presence of 5 μ M ML335 or ML402. Pipette solution contained the following: 150 mM KCl, 3.6 mM CaCl 2 , 10 mM HEPES (pH 7.4 with KOH). Bath solution contained the following: 150 mM RbCl, 2 mM EGTA and 10 mM HEPES (pH 7.4 with RbOH), and was continuously perfused at 200 ml per hour during the experiment. TREK-1 currents were elicited by a voltage step protocol from − 100 mV to + 100 mV, from a -80 mV holding potential (or − 10 mV for K 2P 2.1(G137I) and K 2P 4.1(G124I) in presence of the compounds after exposing the patch to the compound for 30 s at − 80 mV). Data were analysed using Clampfit 9 and Origin 7. Two-electrode voltage-clamp electrophysiology. Two-electrode voltage-clamp recordings were performed on defolliculated stage V-VI Xenopus laevis oocytes 24-48 h after microinjection with 0.15-5 ng cRNA. Oocytes were impaled with borosilicate recording microelectrodes (0.3-3.0 MΩ resistance) backfilled with 3 M KCl. Recording solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , and 2.0 mM MgCl 2 , buffered with 5 mM HEPES, pH 7.4) was perfused at a rate of 3 ml min −1 . Currents were evoked from a − 80 mV holding potential followed by a 300 ms ramp from − 150 mV to + 50 mV. Data were acquired using a GeneClamp 500B amplifier (MDS Analytical Technologies) controlled by pClamp software (Molecular Devices), and digitized at 1 kHz using Digidata 1332A digitizer (MDS Analytical Technologies).
Dose-response experiments were carried by first preparing a DMSO stock solution of each activator at a concentration of 100 mM. Owing to the low solubility of the compounds the highest tested concentrations in recording solution were 100 μ M and 80 μ M for ML335 and ML402, respectively (final concentration of DMSO letter reSeArCH Extended Data Figure 1 | K 2P 2.1 cryst function and structure. a, Exemplar recording from K 2P 2.1 cryst expressed in Xenopus oocytes. Current was elicited from a − 80 mV holding potential followed by a 500 ms ramp from − 150 mV to + 50 mV. letter reSeArCH extended data table 1 | data collection and refinement statistics Values in parentheses are for highest-resolution shell. Each dataset was derived from a single crystal.
